May 1 (Reuters) - Aeterna Zentaris Inc AEZS.TO
* Aeterna Zentaris announces that ZoptEC Phase 3 clinical study of Zoptrex did not achieve its primary endpoint
* Aeterna Zentaris Inc - company expects to submit Macrilen NDA in Q3 of 2017
* Aeterna Zentaris Inc - Zoptrex generally performed no better than comparator drug with respect to secondary efficacy endpoints
* Aeterna Zentaris - median overall survival period for patients treated with Zoptrex was 10.9 months which is not a statistically significant
* Aeterna Zentaris - intention to submit Macrilen NDA in Q3 of 2017 and, if product receives FDA approval, to commercially launch product in Q1 of 2018 Source text for Eikon: ID:nBw5tyz0Xa Further company coverage: AEZS.TO